Repligen (NASDAQ:RGEN) Earns Buy Rating from Analysts at UBS Group

UBS Group began coverage on shares of Repligen (NASDAQ:RGENGet Rating) in a report released on Wednesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $213.00 price objective on the biotechnology company’s stock.

Several other brokerages have also weighed in on RGEN. Craig Hallum cut their price target on Repligen from $286.00 to $274.00 in a research note on Thursday, April 28th. StockNews.com started coverage on Repligen in a research report on Thursday, March 31st. They issued a hold rating for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $288.86.

Repligen Trading Down 0.9 %

Shares of RGEN stock opened at $201.74 on Wednesday. Repligen has a twelve month low of $137.21 and a twelve month high of $327.32. The stock has a 50 day moving average of $162.03 and a 200 day moving average of $172.56. The stock has a market cap of $10.98 billion, a P/E ratio of 79.74 and a beta of 0.95.

Repligen (NASDAQ:RGENGet Rating) last posted its earnings results on Wednesday, April 27th. The biotechnology company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.20. The firm had revenue of $206.40 million during the quarter, compared to analyst estimates of $185.48 million. Repligen had a net margin of 19.86% and a return on equity of 11.13%. The business’s quarterly revenue was up 44.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.68 EPS. On average, research analysts predict that Repligen will post 3.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Anthony Hunt sold 24,802 shares of the stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $200.00, for a total value of $4,960,400.00. Following the completion of the sale, the chief executive officer now directly owns 194,667 shares in the company, valued at $38,933,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Repligen news, CEO Anthony Hunt sold 24,802 shares of the business’s stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $200.00, for a total transaction of $4,960,400.00. Following the transaction, the chief executive officer now owns 194,667 shares of the company’s stock, valued at $38,933,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Karen A. Dawes sold 14,715 shares of the firm’s stock in a transaction on Wednesday, May 25th. The stock was sold at an average price of $150.51, for a total value of $2,214,754.65. Following the completion of the sale, the director now directly owns 76,532 shares of the company’s stock, valued at $11,518,831.32. The disclosure for this sale can be found here. 1.10% of the stock is owned by company insiders.

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently made changes to their positions in the company. HM Payson & Co. purchased a new position in Repligen in the fourth quarter worth approximately $26,000. Harding Loevner LP increased its position in shares of Repligen by 121.3% during the 1st quarter. Harding Loevner LP now owns 177 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 97 shares during the last quarter. Confluence Wealth Services Inc. purchased a new stake in Repligen in the 4th quarter valued at about $27,000. Cambridge Trust Co. acquired a new position in Repligen in the first quarter valued at about $38,000. Finally, Sageworth Trust Co of South Dakota purchased a new position in Repligen during the fourth quarter worth about $46,000. Institutional investors and hedge funds own 86.82% of the company’s stock.

About Repligen

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.